Quarterly ResultMay 11, 2026, 04:38 PM
Catalyst Pharma Q1 Revenue $149.3M, Net Income $63.7M
AI Summary
Catalyst Pharmaceuticals reported strong first quarter 2026 financial results, with total product revenue increasing 5.6% year-over-year to $149.3 million. GAAP net income rose 12.3% to $63.7 million, and diluted GAAP EPS was $0.50. The company also reported a significant reduction in FIRDAPSE royalty rates and ended the quarter with $755.9 million in cash and no funded debt. Due to a prior announcement, the company will not provide forward-looking guidance or host an earnings call.
Key Highlights
- Total Q1 2026 product revenue, net, was $149.3 million, a 5.6% increase year-over-year.
- FIRDAPSE net product revenue increased 18.1% to $98.9 million in Q1 2026.
- AGAMREE net product revenue grew 66.6% to $36.7 million in Q1 2026.
- GAAP net income for Q1 2026 was $63.7 million, up 12.3% year-over-year.
- Diluted GAAP net income per share was $0.50, an 11.1% increase from Q1 2025.
- Cash and cash equivalents totaled $755.9 million as of March 31, 2026, with no funded debt.
- FIRDAPSE royalty rate on net U.S. sales reduced to 6% from a previous maximum of 18.5%.
- FYCOMPA net product revenue decreased 61.3% to $13.8 million due to loss of exclusivity.
Price Impact
More from CPRX